Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis--a multinational cross-sectional study

被引:46
作者
Nast, A. [1 ]
Mrowietz, U. [2 ]
Kragballe, K. [3 ]
de Jong, E. M. G. J. [4 ]
Puig, L. [5 ]
Reich, K. [6 ]
Warren, R. B.
Werner, R. [1 ,7 ]
Kopkow, C. [8 ]
Schmitt, J. [8 ]
机构
[1] Charite, Klin Dermatol Venerol & Allergol, Div Evidence Based Med, D-10117 Berlin, Germany
[2] Univ Med Ctr Schleswig Holstein, Dept Dermatol, Psoriasis Ctr, Kiel, Germany
[3] Aarhus Univ Hosp, Dept Dermatol, DK-8000 Aarhus, Denmark
[4] Radboud Univ Nijmegen, Dept Dermatol, Med Ctr, NL-6525 ED Nijmegen, Netherlands
[5] Univ Autonoma Barcelona, Hosp Santa Creu & Sant Pau, E-08193 Barcelona, Spain
[6] Dermatologikum Hamburg, Hamburg, Germany
[7] Univ Manchester, Manchester Acad Hlth Sci Ctr, Salford Royal NHS Trust, Dermatol Ctr, Manchester, Lancs, England
[8] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Ctr Evidence Based Healthcare, D-01062 Dresden, Germany
关键词
Psoriasis; Treatment barrier; Systemic treatment; Biologic; Cross-sectional study; PRIMARY-CARE; ASSOCIATION; MANAGEMENT; VULGARIS; BURDEN;
D O I
10.1007/s00403-013-1372-3
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Despite the availability of a plethora of approved systemic treatments, high proportions of patients with moderate-to-severe psoriasis do not receive systemic treatment. This study aims at identifying barriers that hinder dermatologists from prescribing systemic treatments for psoriasis. A cross-sectional online survey in six countries (Canada, Germany, Spain, France, Italy, UK) was performed among 300 dermatologists, assessing the relevance of 15 potential barriers towards prescribing acitretin, cyclosporine, methotrexate, adalimumab, etanercept, infliximab and ustekinumab. Multivariate regression analyses were used to explore provider characteristics related to these barriers. Treatment barriers are perceived differently in the countries investigated, with Spanish, Italian and Canadian dermatologists being particularly concerned about the safety of methotrexate and Canadian dermatologists about the safety of cyclosporine. In general, safety concerns were the most important barrier to the use of cyclosporine, (18 % of participants' moderate/9 % strong or very strong barrier). Costs were being perceived as a strong or very strong barrier to the use of the different biologics by 19-24 % of the participants. Overall, country and work place were the most important determinants of treatment barriers. Sex, age, training, position and experience were minor determinants of treatment barriers. Medical reasons such as safety concerns or an inappropriate risk-benefit profile are particularly relevant barriers to the prescription of conventional treatments; whereas for biological treatments, economic reasons such as costs are more prevalent. Country specific analysis showed national differences in the perception of safety. The treatment barriers identified in this exploratory study should be confirmed in further health services research.
引用
收藏
页码:899 / 907
页数:9
相关论文
共 50 条
[41]   Psoriasis severity in moderate to severe psoriatic Greek patients routinely treated with systemic treatment: a cross-sectional and retrospective chart review study (CRYSTAL-Greece) [J].
Rigopoulos, Dimitrios ;
Katsantonis, J. ;
Neofotistou, O. ;
Chasapi, V. ;
Lazaridou, E. ;
Roussaki-Schulze, A. V. ;
Papakonstantis, M. ;
Angelakopoulos, C. ;
Rigatos, P. ;
Aronis, P. ;
Zeglinas, C. ;
Kyriakakis, A. ;
Heatta-Speicher, T. ;
Kollia, A. ;
Antachopoulou, K. ;
Papadavid, E. .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2025, 36 (01)
[42]   Epidemiology of moderate-to-severe psoriasis: a comparison between psoriasis patients treated with biological agents, conventional systemic drugs and topical agents [J].
Marques, Emanuel ;
Paluch, Zoltan ;
Bohac, Petr ;
Slanar, Ondrej ;
Belacek, Jaromir ;
Hercogova, Jana .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) :1435-1448
[43]   Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis [J].
Maul, Julia-Tatjana ;
Maul, Lara, V ;
Didaskalu, Johannes A. ;
Valenzuela, Fernando ;
Romiti, Ricardo ;
Peterson, Hannah ;
Korouri, Edwin ;
Novoa, Farah ;
Oon, Hazel H. ;
Zheng, Min ;
Wu, Jashin J. ;
Thyssen, Jacob P. ;
Egeberg, Alexander ;
Armstrong, April W. ;
Nielsen, Mia-Louise .
ACTA DERMATO-VENEREOLOGICA, 2024, 104
[44]   Characteristics of Pruritus in Various Clinical Variants of Psoriasis: Results of the Multinational, Multicenter, Cross-Sectional Study [J].
Jaworecka, Kamila ;
Kwiatkowska, Dominika ;
Marek, Luiza ;
Tamer, Funda ;
Stefaniak, Aleksandra ;
Szczegielniak, Magdalena ;
Chojnacka-Purpurowicz, Joanna ;
Matlawska, Monika ;
Gulekon, Ayla ;
Szepietowski, Jacek C. ;
Narbutt, Joanna ;
Owczarczyk-Saczonek, Agnieszka ;
Reich, Adam .
LIFE-BASEL, 2021, 11 (07)
[45]   Levels of Physical Activity in Patients with Severe Psoriasis: A Cross-Sectional Questionnaire Study [J].
Torres, Tiago ;
Alexandre, Jose Manuel ;
Mendonca, Denisa ;
Vasconcelos, Carlos ;
Silva, Berta Martins ;
Selores, Manuela .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2014, 15 (02) :129-135
[46]   Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study [J].
Schwarz, Christopher Willy ;
Loft, Nikolai ;
Rasmussen, Mads Kirchheiner ;
Nissen, Christoffer, V ;
Dam, Tomas Norman ;
Ajgeiy, Kawa Khaled ;
Egeberg, Alexander ;
Skov, Lone .
ACTA DERMATO-VENEREOLOGICA, 2021, 101
[47]   Levels of Physical Activity in Patients with Severe Psoriasis: A Cross-Sectional Questionnaire Study [J].
Tiago Torres ;
José Manuel Alexandre ;
Denisa Mendonça ;
Carlos Vasconcelos ;
Berta Martins Silva ;
Manuela Selores .
American Journal of Clinical Dermatology, 2014, 15 :129-135
[48]   Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review [J].
Giampiero Girolomoni ;
Laura Savage ;
Paolo Gisondi ;
Åke Svensson ;
Emmanuel Mahé ;
Matthias Augustin ;
Luis Puig .
Dermatology and Therapy, 2023, 13 :2171-2185
[49]   Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review [J].
Girolomoni, Giampiero ;
Savage, Laura ;
Gisondi, Paolo ;
Svensson, Ake ;
Mahe, Emmanuel ;
Augustin, Matthias ;
Puig, Luis .
DERMATOLOGY AND THERAPY, 2023, 13 (10) :2171-2185
[50]   Understanding Barriers Impacting upon Patient Wellbeing: A Nationwide Italian Survey and Expert Opinion of Dermatologists Treating Patients with Moderate-to-Severe Psoriasis [J].
Prignano, Francesca ;
Argenziano, Giuseppe ;
Bardazzi, Federico ;
Borroni, Riccardo G. ;
Brunasso, Alexandra M. G. ;
Burlando, Martina ;
Cagni, Anna Elisabetta ;
Campione, Elena ;
Cinotti, Elisa ;
Colonna, Fabrizio ;
Cuccia, Aldo ;
Dastoli, Stefano ;
De Pasquale, Rocco ;
De Simone, Clara ;
Di Lernia, Vito ;
Dini, Valentina ;
Fabbrocini, Gabriella ;
Galluzzi, Claudia ;
Giacchetti, Alfredo ;
Giofre, Claudia ;
Lasagni, Claudia ;
Lembo, Serena ;
Loconsole, Francesco ;
Montesu, Maria Antonia ;
Pella, Paolo ;
Piaserico, Stefano ;
Pigatto, Paolo ;
Richetta, Antonio Giovanni ;
Scuotto, Adriana ;
Stroppiana, Elena ;
Venturini, Marina ;
Vinci, Anna Stefania ;
Zichichi, Leonardo ;
Fargnoli, Maria Concetta .
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (01)